We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology Newsfeed
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Your Basket
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • My Lexology
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • My Lexology
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact customerservices@lexology.com

Register

Variations on a theme: five proposed abbreviated approval pathways for biogenerics

Fitzpatrick, Cella, Harper & Scinto

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

USA May 5 2009

In the pharmaceutical context, the term “biologics” generally refers to protein-based medicines that are made in living cells, such as insulin and human growth hormone.

Fitzpatrick, Cella, Harper & Scinto - Christopher E. Loh
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • USA
  • Healthcare & Life Sciences
  • Intellectual Property
  • Fitzpatrick, Cella, Harper & Scinto

Tagged with

  • Biopharmaceutical
  • Pharmaceutical drug
  • Insulin
  • Protein
  • Cell (biology)
  • Growth hormone
  • Reference
  • Metabolic pathway

Popular articles from this firm

  1. Amgen Obtains $70 Million Damages Award Against Hospira For Infringement Of Amgen’s Erythropoetin Patent *
  2. Amgen obtains $70 million damages award against Hospira for erythropoietin patent infringement *
  3. Federal Circuit Clarifies Venue Issues In Patent Cases *
  4. Federal Circuit Suggests That “Insubstantial Differences” Test May Be More Suitable Than “Function-Way-Result” Test For Evaluating Equivalence In Chemical Patent Cases *
  5. 'Repeat infringers' under Digital Millennium Copyright Act not repeat infringers as adjudged by court *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email enquiries@lexology.com.

Send to Create
Powered by Lexology

Related topic hubs

  1. USA
  2. Healthcare & Life Sciences
  3. Intellectual Property

Lexology Navigator Q&A

Compare jurisdictions: Patents

  1. USA
  2. Hong Kong
  3. Indonesia
  4. More...
Robert E. Armstrong
Partner
McDonald Carano Wilson LLP
What our clients say

“I really enjoy Lexology and incorporate into my practice everyday. I find the content very timely and well written. Keep up the good work.”

Back to Top
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • GDPR Compliance
  • RSS feeds
  • Contact
  • Submissions
  • About
  • Login
  • Register
  • Follow on Twitter
  • Search
Globe Business Media Group

© Copyright 2006 - 2018 Globe Business Media Group